Tibet Rhodiola Pharmaceutical Holding (600211.SS) Earnings Analysis
Tibet Rhodiola Pharmaceutical Holding (600211.SS) has no confirmed upcoming earnings date. Trailing P/E 12.84.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 600211.SS next report earnings?
No confirmed upcoming earnings date is currently scheduled for 600211.SS. This page updates as the calendar is published.
600211.SS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2025-09-29 | 0.4792 CNY | n/a | n/a | n/a |
| 2025-08-16 | 0.93 CNY | n/a | n/a | n/a |
| 2025-04-28 | 0.84 CNY | n/a | n/a | n/a |
| 2025-03-14 | 0.805 CNY | n/a | n/a | n/a |
600211.SS valuation and analyst view
| Trailing P/E | 12.84 |
|---|---|
| Trailing EPS | 3.001 CNY |
| Price / book | 3.18 |
| Dividend yield | 4.56% |
| Market cap | 12.45B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Tibet Rhodiola Pharmaceutical Holding (600211.SS)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for 600211.SS. This page updates as the calendar is published.
Did 600211.SS beat earnings last quarter?
Consensus estimate data was not available for 600211.SS's 2025-09-29 report.
What is 600211.SS's current P/E ratio and EPS?
600211.SS trades at a trailing P/E of 12.84 on trailing EPS of 3.0012496432263376 CNY.
What do analysts rate 600211.SS?
600211.SS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.